AC
RCKT icon

Ascend Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Ascend Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$797K Sell
32,373
-119,730
-79% -$2.6M 0.04% 159
2018
Q2 		$2.99M Sell
152,103
-47,844
-24% -$905K 0.14% 124
2018
Q1 		$3.75M Buy
+199,947
New +$3.26M 0.15% 133

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Ascend Capital's RCKT Position: Q3 2018 in Review

Ascend Capital reduced its Rocket Pharmaceuticals (RCKT) stake by 79% in Q3 2018, selling an estimated $2.6M and leaving 32,373 shares worth $797K. The position accounts for 0.04% of the portfolio, ranked #159.

Ascend Capital first reported a position in RCKT in Q1 2018 and has held it in 3 quarters since. The position peaked at $3.75M in Q1 2018. 84 funds tracked by Wall St. Rank hold RCKT as of Q3 2018.

  • Ascend Capital held 32,373 shares of Rocket Pharmaceuticals worth $797K as of Q3 2018.
  • Ascend Capital sold 119,730 Rocket Pharmaceuticals shares in Q3 2018, an estimated $2.6M.
  • Rocket Pharmaceuticals made up 0.04% of Ascend Capital's portfolio in Q3 2018, its #159 holding.
  • Ascend Capital first reported a position in Rocket Pharmaceuticals in Q1 2018 and has held it in 3 quarters since.
  • Ascend Capital's Rocket Pharmaceuticals position peaked at $3.75M in Q1 2018.
  • 84 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.